510(k) Report

FDA applicant

Endovascular Engineering

Menlo Park, CA4 decisions2023–20260 recalls

FDA records 4 decisions for Endovascular Engineering (Menlo Park, CA) from 2023 to 2026: 4 510(k) clearances. Most are in product codes QEW (Peripheral Mechanical Thrombectomy With…) and SHJ (Thrombectomy Whole Blood Return System). Since 2016 its 510(k)s took a median of 93 days from receipt to decision, against 74 for FDA’s reviews in the same codes and years. Its devices cite 5 predicates, 2 of them its own earlier devices. No recall is linked to its devices.

FDA’s records also spell it “Endovascular Engineering, Inc.”.

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) refreshed weekly, last Nov 3, 2026

FIG. A — Illustration, cardiovascular panel, where it files most

How often FDA has decided Endovascular Engineering’s devices, and how often a recall has named them.

FDA decisions per year

1in 2025

2023: 12025: 12026 (partial year): 2
2023high 2 (2026) · low 0 (2024)2026

2026 so far, outlined.

Recalls per year

No recall linked to its devices since 2023.

FIG. 1 — Endovascular Engineering by year, 2023–2026Sources: FDA decision databases, recall and enforcement reports · Data through Oct 25, 2026

Planning a device like Endovascular Engineering’s? A 510(k) Report ranks candidate predicates for your device by lineage, citations and recall history, with the review-time outlook.

See the 510(k) Report

Other applicant names beginning “Endovascular”

FDA records each applicant name separately; these may or may not be the same firm.